Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma [0.03%]
HER2阳性晚期尿路上皮癌抗HER2治疗的发展现状及挑战
Brigida Anna Maiorano,Nazli Dizman,Andrea Necchi
Brigida Anna Maiorano
Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic urothelial carcinoma. Encouraging clinical activity of HER2-directed ADCs, including disitamab vedotin, has been observed in early-phase trials. Rece...
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221-34 [0.03%]
德瓦鲁单抗联合卡介苗治疗卡介苗初治高危非肌层浸润性膀胱癌（POTOMAC）：一项随机、开放标签、III期试验的最终分析《柳叶刀》2025;406:2221-34
Renate Pichler,José Daniel Subiela,Félix Guerrero-Ramos
Renate Pichler
Donghao Lyu,Yifan Liu,Bingnan Lu et al.
Donghao Lyu et al.
Re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol 2026;89:93-5 [0.03%]
丁丁，雷谦，迪金等。基于适配体的正电子发射断层扫描成像可特异性检测残留膀胱癌：一项首次在人类的研究。欧泌尿 2026；89：93-5
Pierre-Etienne Gabriel,Evanguelos Xylinas
Pierre-Etienne Gabriel
Re: Disitamab Vedotin plus Toripalimab in HER2-expressing Advanced Urothelial Cancer [0.03%]
关于维迪西妥单抗联合特瑞普利单抗治疗HER2表达的晚期尿路上皮癌的研究
Ping Liu,Jinbo Chen,Jumei Zhou
Ping Liu
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients [0.03%]
阿比特龙联合雄激素剥夺治疗转移性雄激素敏感性前列腺癌患者的5年生存期分析
Andrew J Armstrong,Daniel P Petrylak,Neal D Shore et al.
Andrew J Armstrong et al.
The ARCHES trial (NCT02677896) showed improved radiographic progression-free survival (primary analysis; 2018) and overall survival (prespecified analysis; 2021) with enzalutamide versus placebo, with concomitant androgen-deprivation therap...
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301) [0.03%]
卡介苗联合丝裂霉素治疗初治的非肌层浸润性膀胱癌：一项随机III期试验（ANZUP 1301）
Dickon Hayne,Alison Y Zhang,Hayley Thomas et al.
Dickon Hayne et al.
Background and objective: Intravesical bacillus Calmette-Guérin (BCG) plus mitomycin (MM) had not been compared rigorously with BCG alone in BCG-naïve, non-muscle-invasive bladder cancer (NMIBC) patients. ...
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer [0.03%]
一项关于新辅助帕博利珠单抗后进行根治性膀胱切除术治疗肌层浸润性膀胱癌的II期研究（PURE-01）最新的5年随访结果更新
Valentina Tateo,Giuseppe Basile,Patrizia Giannatempo et al.
Valentina Tateo et al.
The PURE-01 trial evaluated three cycles of pembrolizumab 200 mg followed by radical cystectomy (RC) in patients with cT2-3b N0 M0 muscle-invasive bladder cancer (MIBC) ineligible for or refusing cisplatin. A total of 155 patients were trea...
Reply to Armando Stabile, Giorgio Gandaglia, Arturo Chiti, and Francesco Montorsi's Letter to the Editor re: Ken Herrmann, Jochen Walz, Steven MacLennan, et al. SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis. Eur Urol. In press. http [0.03%]
关于Armando Stabile，Giorgio Gandaglia，Arturo Chiti和 Francesco Montorsi致编辑的信的回复“SPARC：一项关于前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描分析和报告共识的德尔菲分析。European Urology，在线发表。http
Ken Herrmann,Louise Emmett;SPARC Consortium
Ken Herrmann